Ming-Qing Li Selected Research

interleukin-22 receptor (IL-22R)

1/2015	Blocking IL-22, a potential treatment strategy for adenomyosis by inhibiting crosstalk between vascular endothelial and endometrial stromal cells.
1/2014	L-22 enhances the invasiveness of endometrial stromal cells of adenomyosis in an autocrine manner.
1/2013	IL-22 secreted by decidual stromal cells and NK cells promotes the survival of human trophoblasts.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ming-Qing Li Research Topics

Disease

33	Endometriosis 01/2022 - 10/2011
21	Neoplasms (Cancer) 12/2021 - 10/2011
11	Spontaneous Abortion (Miscarriage) 10/2022 - 05/2010
11	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2021 - 07/2013
9	Hypoxia (Hypoxemia) 12/2021 - 01/2013
7	Inflammation (Inflammations) 01/2021 - 01/2013
6	Endometrial Neoplasms (Endometrial Cancer) 08/2021 - 01/2017
4	Carcinoma (Carcinomatosis) 10/2017 - 07/2013
3	Insulin Resistance 01/2020 - 01/2013
3	Gestational Diabetes (Gestational Diabetes Mellitus) 01/2020 - 01/2018
2	Uterine Hemorrhage (Uterine Bleeding) 01/2022 - 10/2020
2	Urinary Bladder Neoplasms (Bladder Cancer) 12/2018 - 01/2018
2	Uterine Cervicitis (Cervicitis) 10/2017 - 01/2014
2	Pathologic Processes 01/2017 - 01/2013
2	Parasitic Diseases (Parasitic Disease) 11/2015 - 01/2013
2	Adenomyosis 01/2015 - 01/2014
1	Embryo Loss 10/2022

Drug/Important Bio-Agent (IBA)

15	Estrogens (Estrogen)FDA Link 01/2022 - 10/2011
10	CytokinesIBA 01/2022 - 01/2013
6	LigandsIBA 10/2022 - 01/2015
6	Proteins (Proteins, Gene)FDA Link 12/2021 - 05/2010
6	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 01/2013
6	Glucose (Dextrose)FDA LinkGeneric 01/2020 - 01/2013
6	Interleukin-8 (Interleukin 8)IBA 12/2017 - 07/2012
5	InterleukinsIBA 10/2022 - 04/2014
5	Interleukin-22 (IL-22)IBA 10/2019 - 01/2013
5	Biological ProductsIBA 01/2018 - 10/2012
5	Thymic Stromal LymphopoietinIBA 12/2017 - 07/2013
4	Cadherins (E-Cadherin)IBA 10/2022 - 09/2010
4	Sirolimus (Rapamycin)FDA Link 10/2022 - 01/2018
4	ChemokinesIBA 01/2021 - 01/2015
4	Tuberculin (PPD)IBA 01/2021 - 01/2016
4	Interleukin-10 (Interleukin 10)IBA 01/2020 - 01/2013
4	Interleukin-27 (Interleukin 27)IBA 01/2020 - 01/2017
4	MicroRNAs (MicroRNA)IBA 12/2018 - 01/2017
4	Cisplatin (Platino)FDA LinkGeneric 01/2018 - 01/2016
3	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 10/2022 - 01/2018
3	Phosphotransferases (Kinase)IBA 10/2022 - 01/2018
3	LectinsIBA 10/2022 - 01/2018
3	Hormones (Hormone)IBA 01/2021 - 01/2017
3	protopanaxadiolIBA 01/2021 - 01/2017
3	Insulin (Novolin)FDA Link 01/2020 - 01/2013
3	Neutralizing AntibodiesIBA 11/2018 - 12/2015
3	Proliferating Cell Nuclear Antigen (PCNA)IBA 01/2018 - 08/2015
3	matrigelIBA 01/2017 - 01/2013
3	interleukin-22 receptor (IL-22R)IBA 01/2015 - 01/2013
2	Cell Adhesion MoleculesIBA 10/2022 - 01/2021
2	L-SelectinIBA 10/2022 - 01/2021
2	cadherin 5IBA 10/2022 - 01/2021
2	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 10/2022 - 01/2021
2	Leukocyte Common Antigens (CD45 Antigen)IBA 10/2022 - 01/2021
2	E-SelectinIBA 10/2022 - 01/2021
2	IntegrinsIBA 10/2022 - 01/2021
2	Interleukin-17 (Interleukin 17)IBA 01/2022 - 01/2017
2	CholesterolIBA 01/2022 - 01/2013
2	Heme (Haem)IBA 01/2022 - 01/2019
2	EnzymesIBA 01/2021 - 01/2019
2	CollagenIBA 01/2021 - 01/2020
2	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2020 - 02/2019
2	MelatoninIBA 02/2019 - 01/2018
2	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 01/2019 - 10/2012
2	GinsenosidesIBA 01/2018 - 01/2016
2	Pharmaceutical PreparationsIBA 01/2018 - 01/2017
2	Interleukin-33IBA 10/2017 - 01/2014
2	Chemotactic FactorsIBA 01/2017 - 11/2015
2	CCR3 ReceptorsIBA 11/2015 - 01/2013
2	Chemokine CCL17IBA 08/2015 - 01/2015
2	Messenger RNA (mRNA)IBA 10/2011 - 05/2010
1	AcyltransferasesIBA 10/2022
1	2-chloro-5-nitrobenzanilideIBA 10/2022
1	Mannose ReceptorIBA 10/2022
1	PyrophosphatasesIBA 10/2022
1	Hepatocyte Nuclear Factor 4IBA 10/2022
1	Phosphoric Diester Hydrolases (Phosphodiesterases)IBA 10/2022
1	Monoacylglycerol LipasesIBA 10/2022
1	glycerophosphocholine phosphodiesteraseIBA 10/2022
1	Muramidase (Lysozyme)IBA 10/2022
1	Phospholipids (Phosphatides)FDA LinkGeneric 10/2022
1	lysophosphatidic acidIBA 10/2022
1	CXC ChemokinesIBA 10/2022
1	Hypoxia-Inducible Factor 1IBA 10/2022
1	Lysophospholipase (Phospholipase B)IBA 10/2022
1	Mechanistic Target of Rapamycin Complex 1IBA 10/2022
1	Platelet-Derived Growth FactorIBA 10/2022
1	5-(6)-carboxyfluorescein diacetate succinimidyl ester (CFSE)IBA 10/2022
1	Phosphoric Monoester Hydrolases (Phosphatases)IBA 10/2022
1	Epithelial Cell Adhesion MoleculeIBA 10/2022
1	Beclin-1IBA 10/2022
1	Lysophosphatidic Acid ReceptorsIBA 10/2022
1	Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA 10/2022
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 10/2022
1	PPAR gammaIBA 10/2022
1	Macrophage Colony-Stimulating FactorIBA 10/2022
1	6-carboxyfluorescein (carboxyfluorescein)IBA 10/2022
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 10/2022
1	AntigensIBA 10/2022
1	Glyceraldehyde-3-Phosphate Dehydrogenases (GAPD)IBA 10/2022
1	6- (3- (piperazin- 1- yl)propanoyl)benzo(d)oxazol- 2(3H)- oneIBA 10/2022

Therapy/Procedure

3	Therapeutics 06/2019 - 01/2015
2	Aftercare (After-Treatment) 01/2016 - 01/2015